Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis

被引：10

作者：

Best, Sarah A. ^{[1
,2
]}

Vandenberg, Cassandra J. ^{[1
,2
]}

Abad, Etna ^{[3
]}

Whitehead, Lachlan ^{[1
,2
]}

Guiu, Laia ^{[3
]}

Ding, Sheryl ^{[1
,2
]}

Brennan, Margs S. ^{[1
,2
]}

Strasser, Andreas ^{[1
,2
]}

Herold, Marco J. ^{[1
,2
]}

Sutherland, Kate D. ^{[1
,2
]}

Janic, Ana ^{[1
,2
,3
]}

机构：

[1] Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3052, Australia

[2] Univ Melbourne, Dept Med Biol, Melbourne, Vic 3052, Australia

[3] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Doctor Aiguader 88, Barcelona 08003, Spain

来源：

CELL DEATH & DISEASE | 2020年 / 11卷 / 10期

基金：

澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;

关键词：

MESSENGER-RNA STABILITY; CELL-CYCLE ARREST; P53 TARGET WIG-1; TUMOR SUPPRESSION; PUMA; P21; APOPTOSIS; ABSENCE; GENE;

D O I：

10.1038/s41419-020-03066-9

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

TP53 is a critical tumor suppressor that is mutated in approximately 50% of human cancers. Unveiling the downstream target genes of TP53 that fulfill its tumor suppressor function is an area of intense investigation. Zmat3 (also known as Wig-1 or PAG608) is one such downstream target of p53, whose loss in hemopoietic stem cells lacking the apoptosis and cell cycle regulators, Puma and p21, respectively, promotes the development of leukemia. The function of Zmat3 in tumorigenesis however remains unclear. Here, to investigate which oncogenic drivers co-operate with Zmat3 loss to promote neoplastic transformation, we utilized Zmat3 knockout mice in models of c-MYC-driven lymphomagenesis and Kras(G12D)-driven lung adenocarcinoma development. Interestingly, unlike loss of p53, Zmat3 germline loss had little impact on the rate of tumor development or severity of malignant disease upon either the c-MYC or Kras(G12D) oncogenic activation. Furthermore, loss of Zmat3 failed to rescue Kras(G12D) primary lung tumor cells from oncogene-induced senescence. Taken together, we conclude that in the context of c-MYC-driven lymphomagenesis or mutant Kras(G12D)-driven lung adenocarcinoma development, additional co-occurring mutations are required to resolve Zmat3 tumor suppressive activity.

引用

页数：9

共 33 条

[1] THE C-MYC ONCOGENE DRIVEN BY IMMUNOGLOBULIN ENHANCERS INDUCES LYMPHOID MALIGNANCY IN TRANSGENIC MICE [J].